Metrius

Dienogest, the active ingredient in Metrius, is a progestin (synthetic progestogen) presented as an oral tablet for oral use. It is employed in hormonal therapy for endometriosis, menstrual disorders and as a contraceptive.

GNH USA supplies Metrius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metrius is a progestin that modulates hormone‑driven conditions affecting the reproductive system.

Endometriosis: reduces pain and lesion growth by suppressing estrogen‑driven proliferation. Menstrual disorders: stabilises irregular bleeding and alleviates dysmenorrhoea. Contraception: prevents ovulation and creates an endometrial environment unsuitable for implantation.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Breast tenderness: transient discomfort. - Weight gain: modest increase in body mass. - Acne or skin changes: occasional eruptions. - Mood swings: mild emotional variability.

Serious or Rare Side Effects: - Venous thromboembolism: risk of deep‑vein clot formation. - Severe depression or mood disorders: may require medical attention. - Liver dysfunction: abnormal liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - Uterine rupture (very rare): especially in pregnancy, which is contraindicated.

Before initiating therapy, consider the following safety measures.

Pregnancy: contraindicated; avoid use in women who are or may become pregnant. Liver disease: assess hepatic function; use with caution in impairment. Smoking: advise cessation, especially in women over 35, due to cardiovascular risk. Cardiovascular risk: evaluate history of thromboembolic events before prescribing. Drug interactions: review concomitant medications that affect CYP3A4 metabolism. Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Dienogest may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Antifungal agents (e.g., fluconazole): can raise exposure. - Certain antiretrovirals (e.g., ritonavir): potentiate effects. - St John’s wort: may reduce effectiveness by inducing metabolism.

Moderate Interactions (Monitor Closely): - Other hormonal agents (e.g., estrogen‑containing contraceptives): may affect hormonal balance. - NSAIDs: monitor for increased bleeding risk. - Antidepressants (SSRIs): observe for mood changes. - Antiepileptics (e.g., carbamazepine): may lower drug concentration. - Herbal supplements (e.g., ginseng): assess for additive hormonal activity.